Ongoing genomic surveillance shows no SARS-CoV-2 variants currently meeting WHO or ECDC criteria for designation as a variant of concern, with all monitored strains like BA.3.2, NB.1.8.1, and XFG classified only as variants under monitoring or of interest. These Omicron sublineages continue to circulate with mutations that enhance immune escape or transmissibility in some cases, yet they have not produced evidence of substantially increased severity, hospitalization rates, or immune evasion severe enough to trigger a new VOC label through mid-2026. This stability in real-world impact underpins trader consensus around an 85% implied probability that no new variant of concern will emerge before 2027, though continued evolution and surveillance gaps leave room for unexpected shifts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$241,359 Vol.
$241,359 Vol.
$241,359 Vol.
$241,359 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Market Opened: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Ongoing genomic surveillance shows no SARS-CoV-2 variants currently meeting WHO or ECDC criteria for designation as a variant of concern, with all monitored strains like BA.3.2, NB.1.8.1, and XFG classified only as variants under monitoring or of interest. These Omicron sublineages continue to circulate with mutations that enhance immune escape or transmissibility in some cases, yet they have not produced evidence of substantially increased severity, hospitalization rates, or immune evasion severe enough to trigger a new VOC label through mid-2026. This stability in real-world impact underpins trader consensus around an 85% implied probability that no new variant of concern will emerge before 2027, though continued evolution and surveillance gaps leave room for unexpected shifts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions